Carousel01a
Customized managed access, compassionate use, expanded access and named patient programs designed for rare disease therapies, guided by real world evidence and data.
Carousel02a
Does your rare disease commercial strategy need Managed Access expertise to guide your expansion planning?
Carousel03a
RareiTi- a different kind of managed access company.
previous arrow
next arrow

RareiTi offers a new managed access model to the pharmaceutical industry, delivering solutions for named patient, compassionate use and expanded access programs to meet the unmet needs of people and communities across the globe impacted by rare disease. Our managed access programs provide care beyond therapy, combining customizable solutions with white glove service and the ability to deliver real world evidence and data from the point of care. We combine a breadth of global experience, cutting edge technologies and analytics to deliver better outcomes.

Our advisory practice offers business advice and recommendations on the suitability, design and business impact of managed access including compassionate use, expanded access and named patient programs for patients with rare diseases.

We deliver customized global managed access designed to meet complex challenges for patients with a rare disease at the point of care.

RareiTi DATA provides the baseline of our strategic customizable analytics platform to accurately capture real-world patient experiences that measure patient outcomes.

Latest from RareiTi VIEW

Are you ready for the regulatory changes to early access in France?

Changes to the existing ATU include two distinct pathways for drugs/therapies in clinical development and off-label including use in rare disease, that now include a commitment to collection of data.  By Heather Manna, Director of Regulatory Affairs, RareiTi The most recent French Social Security law of Decembe14, 2020 (Article 78- La Loi de financement de…

Read More

Latest Tweets @RareiTi

An experienced senior leadership team

40+ rare disease conditions

50+ biotech and pharma companies

200+ managed access programs: expanded access, compassionate use and named patient programs

100,000s of patients supported with access to treatment

COVID-19 Response

The COVID-19 pandemic is having significant impact on clinical trials globally. Many trials face suspension or closure due to clinical priorities and the impact of social distancing and quarantine.

Clinical trial patients with a rare condition face great challenges; being part of a clinical trial when living with a rare condition can often be the only lifeline available, offering the chance to access novel therapies that could improve life enormously. During the pandemic, not being able to access novel therapies could have a major negative impact on health, disease progression and mortality. In addition, progress toward an approved therapy should not have to be completely stalled because of a lack of ability to collect relevant data.

Follow us on:

     

London  •  Chicago  •  New Jersey

©2021 RareiTi